Clinical Trial Update: Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial studying nabiximols Oromucosal spray for PTSD has been withdrawn after Phase 2/3 development.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Nabiximols Oromucosal Spray (nabiximols)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Post-Traumatic Stress Disorder | Phase 2, Phase 3 | Status: WITHDRAWN